CRISPR & Gene Editing Design
Verve Therapeutics
by Verve Therapeutics, Inc.
Single-course gene editing medicines that permanently lower cardiovascular disease risk from a single treatment
Category
CRISPR & Gene Editing Design
Founded
2018
Headquarters
Cambridge, MA, USA
Overview
Verve Therapeutics is developing gene editing medicines to permanently reduce the risk of cardiovascular disease by making a single base edit in the liver that mimics the protective genetic variants found in people naturally resistant to heart attacks. The company's lead program, VERVE-101, uses adenine base editing to inactivate the PCSK9 gene in liver cells, permanently lowering LDL cholesterol in a manner analogous to a genetic variant (PCSK9 loss-of-function) found in people with lifelong low LDL and dramatically reduced cardiovascular events. Patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease are the initial target population. Phase 1b clinical data from the Heart-1 trial has demonstrated LDL-C reductions of up to 69% sustained at 180+ days following a single infusion of VERVE-101, alongside a favorable safety profile. Verve-102, which uses a next-generation LNP formulation, is advancing into clinical studies. Verve's foundational insight is that cardiovascular disease — the world's leading cause of death — is largely genetic and preventable with the right precision intervention. The company's approach draws on decades of human genetic validation (PCSK9, ANGPTL3, HBB) to select targets with established therapeutic evidence, then applies base editing to create a permanent, medication-free biological state. Co-founded by cardiologist Sekar Kathiresan, the company bridges the gap between human genetics discovery and gene editing therapeutic application.
Key Features
Multi-Editor Support
Design tools for CRISPR-Cas9, Cas12, base editing, and prime editing systems.
Delivery System Optimization
Integrated optimization of delivery vectors including viral vectors, LNPs, and electroporation.
Pre-Validated Guide Libraries
Genome-wide guide RNA libraries for common model organisms ready for experimental use.
Multiplexed Editing Design
Design multi-guide strategies for simultaneous editing at multiple genomic loci.
HDR Template Design
Optimized homology-directed repair template design for precise sequence insertions.
Pros & Cons
Pros
- +Cloud-based design tools enable collaborative gene editing project management across teams
- +Pre-validated guide libraries for common model organisms accelerate experimental design
- +Integration with delivery system optimization (viral vectors, LNPs, electroporation)
- +Regulatory-ready documentation packages support IND applications for gene therapy programs
- +AI-optimized guide RNA design maximizes on-target efficiency while minimizing off-target effects
- +Comprehensive off-target prediction algorithms evaluate billions of potential cleavage sites
Cons
- −Intellectual property landscape for CRISPR technology is complex with multiple competing patents
- −Editing efficiency varies significantly across cell types and genomic loci
- −Regulatory pathways for gene-edited therapies are evolving and differ across jurisdictions
- −Off-target editing effects remain a safety concern especially for therapeutic applications
- −Delivery challenges limit efficient CRISPR component delivery to many tissue types in vivo
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.